Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Equity Average (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Equity Average for 15 consecutive years, with $983.7 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 17.69% to $983.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $983.7 million through Dec 2025, up 17.69% year-over-year, with the annual reading at $923.8 million for FY2025, 20.65% up from the prior year.
  • Equity Average hit $983.7 million in Q4 2025 for Ligand Pharmaceuticals, up from $888.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $983.7 million in Q4 2025 to a low of $621.9 million in Q1 2023.
  • Historically, Equity Average has averaged $777.2 million across 5 years, with a median of $798.5 million in 2021.
  • Biggest five-year swings in Equity Average: fell 22.95% in 2023 and later rose 22.12% in 2024.
  • Year by year, Equity Average stood at $816.6 million in 2021, then fell by 13.44% to $706.9 million in 2022, then decreased by 3.18% to $684.4 million in 2023, then increased by 22.12% to $835.8 million in 2024, then grew by 17.69% to $983.7 million in 2025.
  • Business Quant data shows Equity Average for LGNDZ at $983.7 million in Q4 2025, $888.7 million in Q3 2025, and $811.5 million in Q2 2025.